A carregar...
HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
HER2 receptor tyrosine kinase that is overexpressed in approximately 20% of all breast cancers (BCs) is a poor prognosis factor and a precious target for BC therapy. Trastuzumab is approved by FDA to specifically target HER2 for treating HER2+ BC. However, about 60% of patients with HER2+ breast tum...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5447950/ https://ncbi.nlm.nih.gov/pubmed/28445439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers9050040 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|